Compare T-Mobile Us Inc (TMUS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs Zimmer Biomet Holdings Inc — how do they compare? T-Mobile Us Inc trades at $177.55 (market cap $194.89B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: T-Mobile Us Inc is far larger — about 10.8× Zimmer Biomet Holdings Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| TMUS | ZBH | |
|---|---|---|
Market Cap | $194.89B | $17.97B |
Sector | Media | Health |
52-Week High | $241.67 | $104.26 |
52-Week Low | $167.65 | $79.58 |
Enterprise Value | $311.51B | $25.04B |
Dividend Yield | 2.25% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement (+0.09%) amid a bearish technical signal. The company demonstrates strong fundamentals with $88.3B revenue (2025) and consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80% buy ratings and a $233.20 consensus target, though technical indicators show near-term resistance at $183. Recent developments include CFO transition planning and institutional accumulation by California State Teachers Retirement System.
TMUS presents a compelling growth story with solid profitability metrics and analyst support, though technical weakness and competitive pressures warrant caution. The stock's 28% upside to consensus target offers potential, but investors must weigh strong cash flow generation against rising debt levels and sector-wide pricing pressures evident in recent broadband repricing trends.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
